Movement Disorders in Autoimmune Encephalitis a Cohort
Objective: To analyze the clinical profile of patients with suspected autoimmune encephalitis. Background: Autoimmune encephalitis (AE) is a disease characterized by a diverse range of…Glossography – a novel, computer-vision based technique for assessing and treating involuntary tongue movements in dyskinetic episodes in Parkinson’s disease
Objective: To develop and evaluate a novel deep learning-based computer vision approach for tracking tongue movements in Parkinson's disease (PD) patients with levodopa-induced dyskinesias to…Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias
Objective: To investigate the efficacy of buspirone on levodopa induced dyskinesias (LID) in Parkinson disease (PD) patients Background: LID could be partially mediated by the…Delineating the Molecular and Clinical Spectrum of Epilepsy-Dyskinesia Syndromes in Children (The Epilepsy-Dyskinesia Spectrum Study)
Objective: To understand the spectrum and association of movement and seizure disorders on a clinical and molecular level. Background: Epilepsy-Dyskinesia Syndromes (EDS) are neurological conditions…Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease
Objective: To assess predictability of “On” or “Off” motor states in patients (pts) with advanced Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: Pts with…Identification and Screening of Candidate Genes for Paroxysmal Movement Disorders by Next Generation Sequencing Approach for Developing Molecular Diagnostics.
Objective: To explore the clinical and genetic features of Paroxysmal Movement Disorders by using Whole Exome Sequencing. Background: Paroxysmal movement disorders (PMDs) comprise both paroxysmal…Meta-Analysis of Two Randomized Controlled Trials Assessing the Efficacy of Mesdopetam (IRL790) in Levodopa-Induced Dyskinesia in Parkinson’s Disease
Objective: To evaluate the efficacy of mesdopetam for the treatment of levodopa-induced dyskinesia in Parkinson’s disease (PD-LID), based on two Phase 2 trials. Background: Mesdopetam…ATP1A3-related disorder overlapping syndrome: a case report
Objective: The phenotypic spectrum in dystonic syndromes in ATP1A3-related disorders is wide. History of drug-refractory seizures, developemental delay, incoordination, dysarthria and dysphagia and movement disorders…Increased cholinergic activity in specific brain regions associated with the presence of dyskinesias in Parkinson’s disease: A [18F]-FEOBV PET study
Objective: To explore the role of cholinergic dysfunction in dyskinesia symptoms in people with Parkinson’s disease (PD). Background: Dyskinesias, involuntary and sometimes excessive or uncontrolled…Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment
Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 44
- Next Page »